This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Jul;4(7):402-3.

doi: 10.1038/ncponc0842. Epub 2007 May 22.

Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?

David Ritchie¹

Affiliations

PMID: 17519919
DOI: 10.1038/ncponc0842

Comment

Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?

David Ritchie. Nat Clin Pract Oncol. 2007 Jul.

. 2007 Jul;4(7):402-3.

doi: 10.1038/ncponc0842. Epub 2007 May 22.

Author

David Ritchie¹

Affiliation

¹ Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia. david.ritchie@petermac.org

PMID: 17519919
DOI: 10.1038/ncponc0842

No abstract available

PubMed Disclaimer

Comment on

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG). Forstpointner R, et al. Blood. 2006 Dec 15;108(13):4003-8. doi: 10.1182/blood-2006-04-016725. Epub 2006 Aug 31. Blood. 2006. PMID: 16946304 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.